Opportunities in the SMA market include leveraging the launch of new myostatin inhibitors, expanding Zolgensma formulations to increase patient eligibility, and capitalizing on cheap nusinersen ...

The FDA approved an intrathecal form of Novartis’ spinal muscular atrophy gene therapy Zolgensma on Monday, broadening access ...

On 25 November 2025, Novartis Pharmaceuticals conducted a study is to evaluate the safety, tolerability, and efficacy of the two different treatment combinations of tulmimetostat in participants with ...

-- Muscular Dystrophy Association Calls FDA Approval of Novartis' Itvisma (onasemnogene abeparvovec-brve) a Major Step Forward for the Spinal Muscular Atrophy Community Mary Fiance, National Vice ...

SCHAUMBURG, Ill., Nov. 26, 2025 /PRNewswire/ -- Cure SMA, the leading nonprofit organization dedicated to supporting those impacted by spinal muscular atrophy (SMA), welcomes the FDA approval of ...

Novartis’ Itvisma (onasemnogene) has been approved by the US FDA to treat spinal muscular atrophy (SMA) in children aged two ...

Jeremy Bray, 29, lives with Spinal Muscular Atrophy, a neurodegenerative disorder that causes the loss of motor neurons and ...

Itvisma (onasemnogene abeparvovec-brve) demonstrated improved motor function and stabilization in patients regardless of SMA treatment history in Phase III studiesOne-time dose of Itvisma replaces ...

The FDA has approved Itvisma for the treatment of children two years and older, teens and adults living with spinal muscular ...

A new study finds that men with diabetes have areas of muscle thinning in their gluteus maximus while women show pockets of ...

Basel: Novartis has received approval from the US Food and Drug Administration (FDA) for Itvisma (onasemnogene ...

The US FDA has approved Novartis' new gene therapy, Itvisma, which is for patients aged two and above with spinal muscular ...